Amir Monfaredan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Amir Monfaredan has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alaviyehsadat Hosseininasab
GeneDia Life Science Company, Tehran 1416634793, Iran
1 shared publication - AliAkbar Aghajani Afrouzi
Payame Noor University, Tehran, Iran
1 shared publication - Elahe Motevaseli
Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Fakher Rahim
Osh State University
1 shared publication - Gholamreza Tavoosidana
Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Mahdi Shafiee Sabet
Al-Subtain University of Medical Sciences-International Branch of Tehran University of Medical Sciences, Karbala, Iraq
1 shared publication
Latest Publications
- 24 March 2024
- Published by LLC Science and Innovations in Russian Open Medical Journal
- Vol. 13 (1)
A Microchip For Exosome Isolation That Can Be Impregnated With Imatinib Simultaneously: An In Vitro Analysis
Background and Aims — Exosomes, which are tiny double-layered membranes originating from eukaryotic cells, have been recognized as a valuable natural vehicle for delivering substances because of their optimal size, compatibility with living organisms, strong structure, ability to carry a large amount of cargo, and capacity to be modified on their surface. Methods — Various strategies have been employed to isolate exosomes due to the challenges associated with maintaining their high purity. The current investigation utilized a soft lithography technique to fabricate channels for exosome separation, incorporating immunoaffinity capabilities. Both biochemical and biophysical assays were conducted to assess the quality of isolated exosomes from various sources (serum, cell supernatant, and urine) and compared with a commercially available kit. Results — The current investigation employed a microfluidic method to capture CD63-conjugated magnetic beads, resulting in a very effective separation of exosomes. Based on the data, there were no notable variations in miRNAs that were statistically significant. This demonstrates that the engineered chip successfully achieved the separation of the exosome while preserving the integrity of its nucleic acid components. Conclusion — The results shown that the current methodology effectively isolated exosomes with a high yield rate, purity, and minimal time requirement. The imatinib laden exosomes demonstrated anticancer efficacy against the KYO-1 cell line in all of their forms.
- 24 March 2024
- Published by LLC Science and Innovations in Russian Open Medical Journal
- Vol. 13 (1)
A Microchip For Exosome Isolation That Can Be Impregnated With Imatinib Simultaneously: An In Vitro Analysis
Background and Aims — Exosomes, which are tiny double-layered membranes originating from eukaryotic cells, have been recognized as a valuable natural vehicle for delivering substances because of their optimal size, compatibility with living organisms, strong structure, ability to carry a large amount of cargo, and capacity to be modified on their surface. Methods — Various strategies have been employed to isolate exosomes due to the challenges associated with maintaining their high purity. The current investigation utilized a soft lithography technique to fabricate channels for exosome separation, incorporating immunoaffinity capabilities. Both biochemical and biophysical assays were conducted to assess the quality of isolated exosomes from various sources (serum, cell supernatant, and urine) and compared with a commercially available kit. Results — The current investigation employed a microfluidic method to capture CD63-conjugated magnetic beads, resulting in a very effective separation of exosomes. Based on the data, there were no notable variations in miRNAs that were statistically significant. This demonstrates that the engineered chip successfully achieved the separation of the exosome while preserving the integrity of its nucleic acid components. Conclusion — The results shown that the current methodology effectively isolated exosomes with a high yield rate, purity, and minimal time requirement. The imatinib laden exosomes demonstrated anticancer efficacy against the KYO-1 cell line in all of their forms.